Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06149676 · ClinicalTrials.gov registry record · Early Phase 1
A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections
A Early Phase 1 study of Recurrent Uti, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06149676: Recruiting Early Phase 1 study of Recurrent Uti, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
NCT06149676 is a Early Phase 1 study of Recurrent Uti that is actively recruiting participants, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 35 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06149676, a Early Phase 1 study of Recurrent Uti, is actively recruiting participants, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI episode after enrollment, or they received standard of care treatment.
Primary Outcome
We will look for a reduction the number of UTI episodes before and after the intervention.
Conditions Studied
Interventions
- DRUG Saccharomyces Boulardii 250 MG [Florastor]
Study Locations (1)
Illinois
- Lurie Children's Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2025-12-31 |
| Phase | Early Phase 1 |
What NCT06149676 shows while recruiting
NCT06149676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Recurrent Uti appearing as the primary indexed condition, and to 1 intervention - of which Saccharomyces Boulardii 250 MG [Florastor] is the first listed.
NCT06149676 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06149676 about?
NCT06149676 is a clinical study titled "A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections". Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI episode after enrollment, or they received standard of care treatment.
What is the current status of trial NCT06149676?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2022-02-02. Estimated completion is 2025-12-31.
What conditions does trial NCT06149676 study?
This clinical trial studies the following conditions: Recurrent Uti.
What interventions are being tested in trial NCT06149676?
The interventions under investigation include: Saccharomyces Boulardii 250 MG [Florastor] (DRUG).
Who is sponsoring clinical trial NCT06149676?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06149676 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Uti
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06149676's enrollment target sits among peer trials
35 735th of 2000 higher than 1,254 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI